Efficacy and safety of olezarsen in patients with vs without baseline fibrate use.
Hypertriglyceridemia is associated with increased atherosclerotic cardiovascular disease and pancreatitis risk, yet durable triglyceride reduction remains challenging. Olezarsen, an antisense oligonucleotide targeting APOC3, substantially reduced triglycerides in phase 3 trials.
Hypertriglyceridemia is associated with increased atherosclerotic cardiovascular disease and pancreatitis risk, yet durable triglyceride reduction remains challenging. Olezarsen, an antisense oligonucleotide targeting APOC3, substantially reduced triglycerides in phase 3 trials.
What the study was
- Study design
- Randomized Controlled Trial (inferred)
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- J Clin Lipidol
Why it surfaced
Matched watchlist topic 'Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk'. Study design: Randomized Controlled Trial (inferred). Score: 8/10 (N:1, R:3, D:2, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.